How Low Can You Go? The Radiobiology of Hypofractionation

被引：29

作者：

Brand, D. H. ^{[1
]}

Kirby, A. M. ^{[1
,2
]}

Yarnold, J. R. ^{[1
,2
]}

Somaiah, N. ^{[1
,2
]}

机构：

[1] Inst Canc Res, London, England

[2] Royal Marsden NHS Fdn Trust, London, England

来源：

CLINICAL ONCOLOGY | 2022年 / 34卷 / 05期

关键词：

Hypofractionation; radiobiology; BODY RADIATION-THERAPY; EARLY BREAST-CANCER; CONVENTIONAL RADIOTHERAPY; STEREOTACTIC BODY; FRACTIONATED RADIOTHERAPY; NON-INFERIORITY; FAST-FORWARD; HUMAN-SKIN; SENSITIVITY; TOXICITY;

D O I：

10.1016/j.clon.2022.02.009

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Hypofractionated radical radiotherapy is now an accepted standard of care for tumour sites such as prostate and breast cancer. Much research effort is being directed towards more profoundly hypofractionated (ultrahypofractionated) schedules, with some reaching UK standard of care (e.g. adjuvant breast). Hypo fractionation exerts varying influences on each of the major clinical end points of radiotherapy studies: acute toxicity, late toxicity and local control. This review will discuss these effects from the viewpoint of the traditional 5 Rs of radiobiology, before considering non-canonical radiobiological effects that may be relevant to ultrahypofractionated radiotherapy. The principles outlined here may assist the reader in their interpretation of the wealth of clinical data presented in the tumour site-specific articles in this special issue. (C) 2022 The Authors. Published by Elsevier Ltd on behalf of The Royal College of Radiologists.

引用

页码：280 / 287

页数：8

共 63 条

[1] On the Sensitivity of α/β Prediction to Dose Calculation Methodology in Prostate Brachytherapy [J].

Afsharpour, Hossein ;

Walsh, Sean ;

Fekete, Charles-Antoine Collins ;

Vigneault, Eric ;

Verhaegen, Frank ;

Beaulieu, Luc .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 88 (02) :345-350

[2] Utilizing the genomically adjusted radiation dose (GARD) to personalize adjuvant radiotherapy in triple negative breast cancer management [J].

Ahmed, Kamran A. ;

Liveringhouse, Casey L. ;

Mills, Matthew N. ;

Figura, Nicholas B. ;

Grass, G. Daniel ;

Washington, Iman R. ;

Harris, Eleanor E. ;

Czerniecki, Brian J. ;

Blumencranz, Peter W. ;

Eschrich, Steven A. ;

Scott, Jacob G. ;

Diaz, Roberto ;

Torres-Roca, Javier F. .

EBIOMEDICINE, 2019, 47 :163-169

[3] Hypofractionated versus conventionally fractionated radiotherapy for patients with prostate cancer (HYPRO): late toxicity results from a randomised, non-inferiority, phase 3 trial [J].

Aluwini, Shafak ;

Pos, Floris ;

Schimmel, Erik ;

Krol, Stijn ;

van der Toorn, Peter Paul ;

de Jager, Hanja ;

Alemayehu, Wendimagegn Ghidey ;

Heemsbergen, Wilma ;

Heijmen, Ben ;

Incrocci, Luca .

LANCET ONCOLOGY, 2016, 17 (04) :464-474

[4] TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells [J].

Anbalagan, Selvakumar ;

Stroem, Cecilia ;

Downs, Jessica A. ;

Jeggo, Penny A. ;

McBay, David ;

Wilkins, Anna ;

Rothkamm, Kai ;

Harrington, Kevin J. ;

Yarnold, John R. ;

Somaiah, Navita .

SCIENTIFIC REPORTS, 2021, 11 (01)

[5] Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer (TROG 09.02 CHISEL): a phase 3, open-label, randomised controlled trial [J].

Ball, David ;

Mai, G. Tao ;

Vinod, Shalini ;

Babington, Scott ;

Ruben, Jeremy ;

Kron, Tomas ;

Chesson, Brent ;

Herschtal, Alan ;

Vanevski, Marijana ;

Rezo, Angela ;

Elder, Christine ;

Skala, Marketa ;

Wirth, Andrew ;

Wheeler, Greg ;

Lim, Adeline ;

Shaw, Mark ;

Schofield, Penelope ;

Irving, Louis ;

Solomon, Benjamin .

LANCET ONCOLOGY, 2019, 20 (04) :494-503

[6] Repair halftimes estimated from observations of treatment-related morbidity after CHART or conventional radiotherapy in head and neck cancer [J].

Bentzen, SM ;

Saunders, MI ;

Dische, S .

RADIOTHERAPY AND ONCOLOGY, 1999, 53 (03) :219-226

[7] Estimates of Alpha/Beta (α/β) Ratios for Individual Late Rectal Toxicity Endpoints: An Analysis of the CHHiP Trial [J].

Brand, Douglas H. ;

Bruningk, Sarah C. ;

Wilkins, Anna ;

Fernandez, Katie ;

Naismith, Olivia ;

Gao, Annie ;

Syndikus, Isabel ;

Dearnaley, David P. ;

Tree, Alison C. ;

van As, Nicholas ;

Hall, Emma ;

Gulliford, Sarah .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2021, 110 (02) :596-608

[8] Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial [J].

Brand, Douglas H. ;

Tree, Alison C. ;

Ostler, Peter ;

van der Voet, Hans ;

Loblaw, Andrew ;

Chu, William ;

Ford, Daniel ;

Tolan, Shaun ;

Jain, Suneil ;

Martin, Alexander ;

Staffurth, John ;

Camilleri, Philip ;

Kancherla, Kiran ;

Frew, John ;

Chan, Andrew ;

Dayes, Ian S. ;

Henderson, Daniel ;

Brown, Stephanie ;

Cruickshank, Clare ;

Burnett, Stephanie ;

Duffton, Aileen ;

Griffin, Clare ;

Hinder, Victoria ;

Morrison, Kirsty ;

Naismith, Olivia ;

Hall, Emma ;

van As, Nicholas .

LANCET ONCOLOGY, 2019, 20 (11) :1531-1543

[9] Fractionation and late rectal toxicity [J].

Brenner, DJ .

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2004, 60 (04) :1013-1015

[10]

Bristol, BRISTOL MYERS SQUIBB

← 1 2 3 4 5 6 7 →